Preventive effects of carvedilol on nitrate tolerance - A randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol

Journal of the American College of Cardiology

Volumn 32, Issue 5, 1998, Pages 1201-1206

  Watanabe, Hideki ^a   Kakihana, Masaaki ^b   Ohtsuka, Sadanori ^b   Sugishita, Yasuro ^c  

^a KINU Medical Association Hospital   (Japan)

^b IBARAKI PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; AROTINOLOL; CARVEDILOL; CYCLIC GMP; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; PLACEBO; SUPEROXIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG STRUCTURE; DRUG TOLERANCE; FEMALE; FOREARM BLOOD FLOW; HUMAN; HYPERTENSION; MALE; PLETHYSMOGRAPHY; PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBLINGUAL DRUG ADMINISTRATION; THROMBOCYTE; TRANSDERMAL DRUG ADMINISTRATION; VASODILATATION;

ADRENERGIC ANTAGONISTS; ADULT; AGED; BLOOD FLOW VELOCITY; BLOOD PLATELETS; BLOOD PRESSURE; CARBAZOLES; CYCLIC GMP; DOUBLE-BLIND METHOD; DRUG HYPERSENSITIVITY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FOREARM; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITROGLYCERIN; PROPANOLAMINES; VASODILATOR AGENTS;

EID: 0032212254     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00398-2     Document Type: Article

References (40)

1. Abrams J. Tolerance to organic nitrates. Circulation 1986;74:1181-5.
2. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
3. Zimrin D, Reichek N, Bogin KT, et al. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation 1988;77:1376-84.
4. Fung H-L. Solving the mystery of nitrate tolerance. A new scent on the trail? Circulation 1993;88:322-4.
5. Parker JD, Farrel B, Fenton T, Cohanim MA, Parker JO. Counterregulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84:2336-45.
6. Dupuis J, Lalonde G, Lemieux R, Rouleau J. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990;16:923-31.
7. Waldman SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol 1986;35:3525-31.
8. Schröder H, Leitman D, Bennett B, Waldman S, Murad F. Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts. J Pharmacol Exp Ther 1988;245:413-8.
9. Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular Superoxide anion production in nitrate tolerance. J Clin Invest 1995;95:187-94.
10. Packer M, Colucci WS, Sackner BJ, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-9.
11. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group [see comments]. N Engl J Med 1996;334:1349-55.
12. Australia/New Zealand Heart Failure Research Collaborative G. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997;349:375-80.
13. Feuerstein GZ, Ruffolo RRJ. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996;17 Suppl B:24-9.
14. Yue T-L, Mckenna PJ, Lysko PG, et al. SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur J Pharmacol 1994;251:237-43.
15. Yue T-L, Cheny HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoreceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-8.
16. Ruffulo R, Gelai M, Heible J, Willette R, Nichols A. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38 Suppl 2:882-8.
17. Miyagishi A, Nakahara H, Hara Y. Adrenoceptor blocking effects of arotinolol, a new combined alpha- and beta-adrenoceptor blocking agent. Arch Int Pharmacodyn Ther 1984;271:249-62.
18. Nishida K, Niki S, Furukawa K, et al. Effects of S-596, a new beta-adrenoceptor blocking agent on the left ventricular performance of normal subjects during exercise. Jpn Heart J 1985;26:437-49.
19. Watanabe H, Kakihana M, Ohtsuka S, Enomoto T, Yasui K, Sugishita Y. Platelet cyclic GMP: a potentially useful indicator to evaluate the effects of nitroglycerin and nitrate tolerance. Circulation 1993;88:29-36.
20. Honma M, Satoh T, Takezawa J, Ui M. An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small volume samples from blood and tissue. Biochem Med 1977;18:257-73.
21. Packer M. What causes tolerance to nitroglycerin? The 100 year old mystery continues. J Am Coll Cardiol 1990;16:932-5.
22. Mangione NJ, Glasser SP. Phenomenon of nitrate tolerance. Am Heart J 1994;128:137-46.
23. Axelsson KL, Anderson RG. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol 1983;88:71-9.
24. Needleman P, Johnson EMJ. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973;184:709-15.
25. Feelisch M, Nack EA. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987;139:19-30.
26. Boesgaard S, Aldershvile J, Pedersen F, Pietersen A, Madsen J, Grande P. Continuous N-acetylcysteine treatment and development of nitrate tolerance in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991;17:889-93.
27. Pizzulli L, Hagendorff A, Zirbes M, et al. Influence of captopril on nitroglycerin-mediated vasodilation and development of nitrate tolerance in arterial and venous circulation. Am Heart J 1996;131:342-9.
28. Katz RJ, Levy WS, Buff L, Wasserman AG. Prevention of nitrate tolerance with angiotensin converting enzyme inhibitors. Circulation 1991;83:1271-7.
29. Parker JD, Parker JO. Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counterregulatory response during continuous therapy with nitroglycerin. J Am Coll Cardiol 1993;21:1445-53.
30. Münzel T, Bassenge E. Long-term angiotensin-converting enzyme inhibition with high-dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Circulation 1996;93:2052-8.
31. Bassenge E, Fink B. Tolerance to nitrates and simultaneous upregulation of platelet activity prevented by enhancing antioxidant state. Naunyn Schmiedeberg Arch Pharmacol 1996;353:363-7.
32. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation 1997;96:2545-50.
33. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of ascorbate on the preventive effect of nitrate tolerance in patients with congestive heart failure. Circulation 1998;97:886-91.
34. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of the preventive effect of supplemental oral vitamin C on attenuation of development of nitrate tolerance. J Am Coll Cardiol 1998;31:1323-9.
35. Elkayam U. Prevention of nitrate tolerance with concomitant administration of hydralazine. Can J Cardiol 1996;12 Suppl C17C-21C.
36. Parker JD, Parker AB, Farrell B, Parker JO. The effect of hydralazine on the development of tolerance to continuous nitroglycerin. J Pharmacol Exp Ther 1997;280:866-75.
37. Bowen R, Haslam R. Effects of nitrovasodilators on platelet cyclic nucleotide levels in rabbit blood; role for cyclic AMP in synergistic inhibition of platelet function by SIN-1 and prostaglandin E1. J Cardiovasc Pharmacol 1991;17:424-33.
38. Pohl U, Busse R. EDRF increase cyclic GMP in platelets during passage through the coronary vascular bed. Circ Res 1989;65:1798-803.
39. Rapoport RM, Murad F. Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP. J Cyclic Nucleotide Protein Phosphor Res 1983;9:281-96.
40. Glass DB, Frey WH, Carr DW, Goldberg ND. Stimulation of human platelet guanylate cyclase by fatty acid. J Biol Chem 1977;252:1279-85.